The healthcare sector slipped in a mixed day for the broader market, as PCE data kept inflation worries alive with readings well above the Fed's 2% target.

A next-generation weight-loss drug from Eli Lilly when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study. The experimental injection, eloralintide, which mimics a hormone called amylin that helps signal fullness after eating, was studied in combination with a Zepbound shot in patients with Type 2 diabetes. Patients on the highest dose of the combination lost an average of 23.3% of their body weight over roughly 11 months while those on Zepbound alone lost an average of 14.8% of their weight.

United Therapeutics picked up a win in its patent lawsuit against rival Liquidia when a federal judge ruled that two of United Therapeutics' claims were valid and infringed upon. Shares climbed 14%, its biggest single-day gain in over a year. Liquidia shares, meanwhile, were nearly cut in half.